Compare IDEXX Laboratories, Inc. (IDXX) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Vital Farms Inc — how do they compare? IDEXX Laboratories, Inc. trades at $571 (market cap $46.22B), while Vital Farms Inc trades at $11.45 (market cap $496.50M). The key difference: IDEXX Laboratories, Inc. is far larger — about 93.1× Vital Farms Inc's market cap, and IDEXX Laboratories, Inc. is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals.
| IDXX | VITL | |
|---|---|---|
Market Cap | $46.22B | $496.50M |
Sector | Health | Consumer Staples |
52-Week High | $766.68 | $52.41 |
52-Week Low | $526.44 | $8.28 |
Enterprise Value | $47.12B | $583.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Vital Farms (VITL) trades at $11.52, up 2.31% today, amid bearish technical signals and challenging fundamentals. The stock shows oversold conditions with RSI at 29.21, while recent Q2 2026 results revealed a $0.47 per share loss despite beating revenue estimates. The company secured $125 million in financing to navigate industry oversupply pressures and elevated costs affecting profitability.
While analyst consensus remains positive with a $13.00 price target and no sell ratings, near-term headwinds from margin compression and net cash outflows pose significant risks. The stock's valuation appears reasonable with P/E of 11.77 and P/S of 0.67, but investors should monitor execution on cost management and revenue stabilization for sustainable recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
